Viking Therapeutics Eyes 2029 Obesity Drug Launch, Tests Less-Frequent Dosing

Viking Therapeutics (NASDAQ:VKTX) is preparing for a potential 2029 launch of its obesity drug candidate VK2735 while studying whether patients can maintain weight loss with less frequent injections or a daily oral tablet, CEO Brian Lian said at the Jefferies Global Healthcare Conference in London.

Lian said the company is open to interest from larger partners but is also building the capacity to launch independently. Viking has four Phase 3 trials underway, with the first Phase 3 data expected in the second half of 2027 and oral Phase 3 results likely in 2028, he said.

Maintenance Studies Explore Dosing Options

Viking reported initial results from a VK2735 maintenance study in September and presented additional details at ObesityWeek. Participants received weekly injections for 21 weeks before moving to injections every other week or monthly for a further 12 weeks.

Lian said gastrointestinal adverse events, including nausea, vomiting, constipation and diarrhea, were low during dose escalation and fell substantially afterward. During the maintenance period, he said, tolerability was similar to placebo. The company also observed reductions in ApoB, non-HDL cholesterol and triglycerides that appeared to track with weight loss.

Both less-frequent dosing groups showed a slight initial rebound in weight before the maintenance signal improved during weeks eight through 12, Lian said. By contrast, the placebo group regained about 40% of its initial weight loss by week 12. He said Viking does not yet have all of the drug exposure data from the study and does not know what caused the pattern in the treatment groups.

A second maintenance study is enrolling participants. After 21 weeks of weekly injections, some participants will transition to daily oral doses that Lian said range from approximately 10 milligrams to 55 milligrams for 12 weeks. The study also includes six injection arms testing higher every-other-week and monthly doses than those used in the first study. Results are expected around mid-2027.

Lian said Viking is also exploring maintenance doses in extensions of its VANQUISH studies, including a 35-milligram monthly dose. The company hopes the data could eventually support information in a product label, though he said it could also present and publish the findings if they are not included.

The oral formulation contains the same active ingredient as the injection and is being tested in the Phase 3 SUNRISE-1 obesity study and SUNRISE-2 study in people with obesity and diabetes. Lian said Viking hopes mid-to-high oral doses will maintain at least 75% of the initial weight loss after switching from injections, but the outcome remains unknown.

Commercial Plans and Supply

Viking is speaking with direct-to-consumer providers, parties focused on cash-paying customers and payers as it evaluates distribution and coverage options, Lian said. The company has added commercial, market access and medical affairs staff and plans to expand the team as it approaches commercialization.

“We’ve always felt a larger party being involved would generate more value from the program,” Lian said. “That said, we’re also preparing to launch as an independent entity.”

On manufacturing, Lian said Viking has a partnership with CordenPharma for multi-ton quantities of active pharmaceutical ingredient and services for vials, syringes, auto-injectors and tablets. Viking has added three other multi-ton active-ingredient suppliers and plans to build redundancy for finished products, he said.

Amylin Candidate Advances

Viking’s amylin candidate VK3019 is completing a single ascending-dose study in humans. A multiple ascending-dose study is planned for the first quarter of 2027, with four-week data expected toward the end of that year, Lian said.

The company sees potential for VK3019 both on its own and in combination with VK2735. Combination toxicology studies are underway, and Lian said initial combination studies would likely follow the multiple-dose results. Viking also hopes to bring a longer-acting follow-on amylin candidate into clinical testing in 2027, with a potential goal of monthly dosing.

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2012, it develops medicines for metabolic and endocrine disorders and does not have commercially marketed products. The company’s pipeline includes VK2735, an investigational drug that targets the GLP-1 and GIP receptors and is being developed for obesity, and VK2809, a thyroid hormone receptor beta agonist being studied for metabolic and liver conditions. Viking is also developing VK0214 for X-linked adrenoleukodystrophy, a rare genetic disorder.